Parametric Portfolio Associates LLC Purchases 3,352 Shares of Acceleron Pharma Inc (NASDAQ:XLRN)

Share on StockTwits

Parametric Portfolio Associates LLC raised its holdings in Acceleron Pharma Inc (NASDAQ:XLRN) by 14.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,346 shares of the biopharmaceutical company’s stock after purchasing an additional 3,352 shares during the quarter. Parametric Portfolio Associates LLC owned 0.05% of Acceleron Pharma worth $1,123,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of XLRN. Marshall Wace LLP raised its position in Acceleron Pharma by 20,146.2% during the 1st quarter. Marshall Wace LLP now owns 208,333 shares of the biopharmaceutical company’s stock worth $9,702,000 after purchasing an additional 207,304 shares during the last quarter. Marshall Wace North America L.P. boosted its stake in shares of Acceleron Pharma by 6,720.3% in the 1st quarter. Marshall Wace North America L.P. now owns 383,166 shares of the biopharmaceutical company’s stock worth $17,844,000 after buying an additional 377,548 shares during the last quarter. MetLife Investment Advisors LLC lifted its stake in Acceleron Pharma by 10.9% in the first quarter. MetLife Investment Advisors LLC now owns 19,308 shares of the biopharmaceutical company’s stock valued at $899,000 after purchasing an additional 1,902 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its stake in Acceleron Pharma by 12.6% in the first quarter. Metropolitan Life Insurance Co NY now owns 13,963 shares of the biopharmaceutical company’s stock valued at $650,000 after purchasing an additional 1,563 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Acceleron Pharma by 6.3% in the first quarter. FMR LLC now owns 7,363,953 shares of the biopharmaceutical company’s stock worth $342,939,000 after purchasing an additional 435,414 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

XLRN opened at $39.47 on Friday. The company has a quick ratio of 17.11, a current ratio of 17.11 and a debt-to-equity ratio of 0.05. Acceleron Pharma Inc has a 52-week low of $37.01 and a 52-week high of $59.08. The firm’s fifty day simple moving average is $42.80 and its two-hundred day simple moving average is $42.34.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). The company had revenue of $27.67 million for the quarter, compared to analysts’ expectations of $28.72 million. Acceleron Pharma had a negative net margin of 318.84% and a negative return on equity of 29.51%. The business’s revenue for the quarter was up 649.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.63) earnings per share. Equities research analysts expect that Acceleron Pharma Inc will post -2.33 EPS for the current year.

Several analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of Acceleron Pharma in a research report on Tuesday, September 17th. Oppenheimer set a $58.00 price target on shares of Acceleron Pharma and gave the company a “buy” rating in a research report on Tuesday, September 17th. Citigroup reduced their price target on shares of Acceleron Pharma from $61.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. BidaskClub cut shares of Acceleron Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Leerink Swann dropped coverage on shares of Acceleron Pharma in a research note on Tuesday, September 17th. Six analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Acceleron Pharma presently has an average rating of “Buy” and a consensus target price of $57.83.

In other Acceleron Pharma news, VP Adam M. Veness sold 824 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.20, for a total transaction of $37,244.80. Following the transaction, the vice president now directly owns 16,124 shares of the company’s stock, valued at $728,804.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Adam M. Veness sold 3,268 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $45.00, for a total transaction of $147,060.00. Following the transaction, the vice president now directly owns 16,925 shares in the company, valued at $761,625. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,228 shares of company stock worth $1,138,448. Insiders own 2.50% of the company’s stock.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Read More: Compound Interest

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Parametric Portfolio Associates LLC Purchases 3,352 Shares of Acceleron Pharma Inc
Parametric Portfolio Associates LLC Purchases 3,352 Shares of Acceleron Pharma Inc
Tabula Rasa HealthCare Inc  Shares Acquired by Parametric Portfolio Associates LLC
Tabula Rasa HealthCare Inc Shares Acquired by Parametric Portfolio Associates LLC
Vanguard Group Inc. Has $70.92 Million Stock Position in Northstar Realty Europe Corp
Vanguard Group Inc. Has $70.92 Million Stock Position in Northstar Realty Europe Corp
153,444 Shares in Qudian Inc –  Acquired by Parametric Portfolio Associates LLC
153,444 Shares in Qudian Inc – Acquired by Parametric Portfolio Associates LLC
Vanguard Group Inc. Has $71.93 Million Holdings in Stars Group Inc
Vanguard Group Inc. Has $71.93 Million Holdings in Stars Group Inc
Cytokinetics, Inc.  Shares Bought by Parametric Portfolio Associates LLC
Cytokinetics, Inc. Shares Bought by Parametric Portfolio Associates LLC


© 2006-2019 Ticker Report